Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totaling 321,350 shares, a decline of 12.7% from the December 31st total of 368,262 shares. Based on an average trading volume of 383,032 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.2% of the shares of the stock are short sold. Approximately 2.2% of the shares of the stock are short sold. Based on an average trading volume of 383,032 shares, the days-to-cover ratio is presently 0.8 days.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. Wall Street Zen cut shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, D. Boral Capital reiterated a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Thursday, December 4th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Hoth Therapeutics Stock Down 4.3%

Shares of HOTH opened at $0.84 on Wednesday. The company has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.29. The stock has a market cap of $13.01 million, a price-to-earnings ratio of -0.79 and a beta of 0.56. Hoth Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.12.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.20). Equities research analysts expect that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Lido Advisors LLC acquired a new position in shares of Hoth Therapeutics in the 3rd quarter valued at $32,000. Kestra Private Wealth Services LLC bought a new stake in Hoth Therapeutics during the third quarter worth about $51,000. Geode Capital Management LLC raised its position in Hoth Therapeutics by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after acquiring an additional 9,071 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics in the 3rd quarter valued at about $184,000. Finally, Citadel Advisors LLC bought a new stake in Hoth Therapeutics in the third quarter valued at approximately $232,000. 7.08% of the stock is currently owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.